Lucie M Turcotte1, John A Whitton2, Debra L Friedman2, Sue Hammond2, Gregory T Armstrong2, Wendy Leisenring2, Leslie L Robison2, Joseph P Neglia2. 1. Lucie M. Turcotte and Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; John A. Whitton and Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Debra L. Friedman, Vanderbilt University School of Medicine, Nashville; Gregory T. Armstrong and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; and Sue Hammond, Ohio State University, Columbus, OH. turc0023@umn.edu. 2. Lucie M. Turcotte and Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; John A. Whitton and Wendy Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Debra L. Friedman, Vanderbilt University School of Medicine, Nashville; Gregory T. Armstrong and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; and Sue Hammond, Ohio State University, Columbus, OH.
Abstract
PURPOSE: Survivors of childhood cancer have an increased risk for subsequent neoplasms (SNs), but the incidence beyond the age of 40 years and associations with therapeutic exposures have not been well described. PATIENTS AND METHODS: Among 14,364 survivors of childhood cancer diagnosed between 1970 and 1986, 3,171 had an attained age of 40 years or older at the time of last contact. Cumulative incidence of SNs, standardized incidence ratios (SIRs), excess absolute risk of subsequent malignant neoplasms (SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated. RESULTS: In total, 679 SNs were diagnosed in patients age 40 years or older. These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, and 43 other benign neoplasms. At age 55 years, the cumulative incidence of new SNs and SMNs occurring after age 40 years was 34.6% (95% CI, 28.7 to 40.6) and 16.3% (95% CI, 11.7 to 20.9), respectively. Survivors were twice as likely as the general population to receive a diagnosis of SMN after age 40 years (SIR, 2.2; 95% CI, 1.9 to 2.5). Among SMNs, risk was increased for breast cancer (SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR, 1.9; 95% CI, 1.0 to 3.5). Female sex (RR, 1.9; 95% CI, 1.3 to 2.6; P < .001) and therapeutic radiation exposure (RR, 2.2; 95% CI, 1.4 to 3.3; P < .001) were associated with an increased for risk for SMN in multivariable analysis. CONCLUSION: Even after age 40 years, survivors of childhood cancer remain at increased risk for treatment-related SNs. These data suggest the need for life-long monitoring and should inform anticipatory guidance provided to survivors of childhood cancer.
PURPOSE: Survivors of childhood cancer have an increased risk for subsequent neoplasms (SNs), but the incidence beyond the age of 40 years and associations with therapeutic exposures have not been well described. PATIENTS AND METHODS: Among 14,364 survivors of childhood cancer diagnosed between 1970 and 1986, 3,171 had an attained age of 40 years or older at the time of last contact. Cumulative incidence of SNs, standardized incidence ratios (SIRs), excess absolute risk of subsequent malignant neoplasms (SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated. RESULTS: In total, 679 SNs were diagnosed in patients age 40 years or older. These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, and 43 other benign neoplasms. At age 55 years, the cumulative incidence of new SNs and SMNs occurring after age 40 years was 34.6% (95% CI, 28.7 to 40.6) and 16.3% (95% CI, 11.7 to 20.9), respectively. Survivors were twice as likely as the general population to receive a diagnosis of SMN after age 40 years (SIR, 2.2; 95% CI, 1.9 to 2.5). Among SMNs, risk was increased for breast cancer (SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR, 1.9; 95% CI, 1.0 to 3.5). Female sex (RR, 1.9; 95% CI, 1.3 to 2.6; P < .001) and therapeutic radiation exposure (RR, 2.2; 95% CI, 1.4 to 3.3; P < .001) were associated with an increased for risk for SMN in multivariable analysis. CONCLUSION: Even after age 40 years, survivors of childhood cancer remain at increased risk for treatment-related SNs. These data suggest the need for life-long monitoring and should inform anticipatory guidance provided to survivors of childhood cancer.
Authors: Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan Journal: Ann Intern Med Date: 2012-06-05 Impact factor: 25.391
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Chaya S Moskowitz; Joanne F Chou; Suzanne L Wolden; Jonine L Bernstein; Jyoti Malhotra; Danielle Novetsky Friedman; Nidha Z Mubdi; Wendy M Leisenring; Marilyn Stovall; Sue Hammond; Susan A Smith; Tara O Henderson; John D Boice; Melissa M Hudson; Lisa R Diller; Smita Bhatia; Lisa B Kenney; Joseph P Neglia; Colin B Begg; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-04-21 Impact factor: 44.544
Authors: Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2013-02-15 Impact factor: 3.167
Authors: A S Pappo; G T Armstrong; W Liu; D K Srivastava; A McDonald; W M Leisenring; S Hammond; M Stovall; J P Neglia; L L Robison Journal: Pediatr Blood Cancer Date: 2012-08-08 Impact factor: 3.167
Authors: Leslie L Robison; Gregory T Armstrong; John D Boice; Eric J Chow; Stella M Davies; Sarah S Donaldson; Daniel M Green; Sue Hammond; Anna T Meadows; Ann C Mertens; John J Mulvihill; Paul C Nathan; Joseph P Neglia; Roger J Packer; Preetha Rajaraman; Charles A Sklar; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Milena Maule; Ghislaine Scélo; Guido Pastore; Paul Brennan; Kari Hemminki; Elizabeth Tracey; Risto Sankila; Elisabete Weiderpass; Jorgen H Olsen; Mary L McBride; David H Brewster; Vera Pompe-Kirn; Erich V Kliewer; Kee Seng Chia; Jon M Tonita; Carmen Martos; Jon G Jonasson; Franco Merletti; Paolo Boffetta Journal: J Natl Cancer Inst Date: 2007-05-16 Impact factor: 13.506
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Lucie M Turcotte; Qi Liu; Yutaka Yasui; Michael A Arnold; Sue Hammond; Rebecca M Howell; Susan A Smith; Rita E Weathers; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia Journal: JAMA Date: 2017-02-28 Impact factor: 56.272
Authors: Zhaoming Wang; Carmen L Wilson; John Easton; Andrew Thrasher; Heather Mulder; Qi Liu; Dale J Hedges; Shuoguo Wang; Michael C Rusch; Michael N Edmonson; Shawn Levy; Jennifer Q Lanctot; Eric Caron; Kyla Shelton; Kelsey Currie; Matthew Lear; Aman Patel; Celeste Rosencrance; Ying Shao; Bhavin Vadodaria; Donald Yergeau; Yadav Sapkota; Russell J Brooke; Wonjong Moon; Evadnie Rampersaud; Xiaotu Ma; Ti-Cheng Chang; Stephen V Rice; Cynthia Pepper; Xin Zhou; Xiang Chen; Wenan Chen; Angela Jones; Braden Boone; Matthew J Ehrhardt; Matthew J Krasin; Rebecca M Howell; Nicholas S Phillips; Courtney Lewis; Deokumar Srivastava; Ching-Hon Pui; Chimene A Kesserwan; Gang Wu; Kim E Nichols; James R Downing; Melissa M Hudson; Yutaka Yasui; Leslie L Robison; Jinghui Zhang Journal: J Clin Oncol Date: 2018-05-30 Impact factor: 44.544
Authors: Smita Bhatia; Yanjun Chen; F Lennie Wong; Lindsey Hageman; Kandice Smith; Bruce Korf; Ashley Cannon; Daniel J Leidy; Alejandro Paz; Joseph E Andress; Gregory K Friedman; Katie Metrock; Joseph P Neglia; Michael Arnold; Lucie M Turcotte; Peter de Blank; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; D Wade Clapp; Kevin Shannon; Jean L Nakamura; Michael J Fisher Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544
Authors: Arin L Madenci; Bryan V Dieffenbach; Qi Liu; Daisuke Yoneoka; Jamie Knell; Todd M Gibson; Yutaka Yasui; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Kevin R Krull; Gregory T Armstrong; Kevin C Oeffinger; Andrew J Murphy; Brent R Weil; Christopher B Weldon Journal: Cancer Date: 2019-07-19 Impact factor: 6.860
Authors: Lucie M Turcotte; Joseph P Neglia; Raoul C Reulen; Cecile M Ronckers; Flora E van Leeuwen; Lindsay M Morton; David C Hodgson; Yutaka Yasui; Kevin C Oeffinger; Tara O Henderson Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544
Authors: Lindsay M Morton; Danielle M Karyadi; Stephen W Hartley; Megan N Frone; Joshua N Sampson; Rebecca M Howell; Joseph P Neglia; Michael A Arnold; Belynda D Hicks; Kristine Jones; Bin Zhu; Casey L Dagnall; Eric Karlins; Meredith S Yeager; Wendy M Leisenring; Yutaka Yasui; Lucie M Turcotte; Susan A Smith; Rita E Weathers; Jeremy Miller; Byron S Sigel; Diana M Merino; Amy Berrington de Gonzalez; Smita Bhatia; Leslie L Robison; Margaret A Tucker; Gregory T Armstrong; Stephen J Chanock Journal: JCO Precis Oncol Date: 2020-08-21